Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).

Mollica V, Massari F, Fujita K, Giannatempo P, Grande E, Büttner T, Bourlon MT, Taha T, Fukuokaya W, Myint ZW, Pichler R, Binz K, Molina-Cerrillo J, Kopecky J, de Liaño AG, Kucharz J, Fiala O, Matrana MR, Kopp RM, Di Civita MA, Zgura A, Ansari J, Kihnel R, De Felice F, Angel M, Monteiro FSM, Soares A, Urun Y, Buti S, Santini D, Santoni M

Open source

DOI: 10.1007/s00262-026-04328-9
Published: 2026 Mar 24
Container: Cancer immunology, immunotherapy : CII
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00262-026-04328-9,
  title = {Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).},
  author = {Mollica V and Massari F and Fujita K and Giannatempo P and Grande E and Büttner T and Bourlon MT and Taha T and Fukuokaya W and Myint ZW and Pichler R and Binz K and Molina-Cerrillo J and Kopecky J and de Liaño AG and Kucharz J and Fiala O and Matrana MR and Kopp RM and Di Civita MA and Zgura A and Ansari J and Kihnel R and De Felice F and Angel M and Monteiro FSM and Soares A and Urun Y and Buti S and Santini D and Santoni M},
  year = {2026},
  journal = {Cancer immunology, immunotherapy : CII},
  doi = {10.1007/s00262-026-04328-9},
  url = {https://doi.org/10.1007/s00262-026-04328-9}
}

RIS

TY  - JOUR
TI  - Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).
AU  - Mollica V
AU  - Massari F
AU  - Fujita K
AU  - Giannatempo P
AU  - Grande E
AU  - Büttner T
AU  - Bourlon MT
AU  - Taha T
AU  - Fukuokaya W
AU  - Myint ZW
AU  - Pichler R
AU  - Binz K
AU  - Molina-Cerrillo J
AU  - Kopecky J
AU  - de Liaño AG
AU  - Kucharz J
AU  - Fiala O
AU  - Matrana MR
AU  - Kopp RM
AU  - Di Civita MA
AU  - Zgura A
AU  - Ansari J
AU  - Kihnel R
AU  - De Felice F
AU  - Angel M
AU  - Monteiro FSM
AU  - Soares A
AU  - Urun Y
AU  - Buti S
AU  - Santini D
AU  - Santoni M
PY  - 2026
JO  - Cancer immunology, immunotherapy : CII
DO  - 10.1007/s00262-026-04328-9
UR  - https://doi.org/10.1007/s00262-026-04328-9
ER  -

APA

V, M., F, M., K, F., P, G., E, G., T, B., MT, B., T, T., W, F., ZW, M., R, P., K, B., J, M., J, K., AG, D. L., J, K., O, F., MR, M., RM, K., MA, D. C., A, Z., J, A., R, K., F, D. F., M, A., FSM, M., A, S., Y, U., S, B., D, S., & M, S. (2026). Real-world effectiveness of avelumab, pembrolizumab, and enfortumab vedotin in patients with advanced urothelial carcinoma with squamous differentiation (ARON-2EV).. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04328-9

Source records

pubmed · retrieved 2026-09-26T05:59:31.358Z